22nd Century’s Proprietary SPECTRUM® Cigarettes Identified as Crucial Tool in Human Addiction Studies
June 16 2016 - 9:44AM
Business Wire
Proprietary Very Low Nicotine Cigarettes
Found to Have Reduced Levels of the Cancer Causing Compounds NNN
and NNK
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction,
announced today that scientists with The Centers for Disease
Control and Prevention (CDC) published a detailed characterization
of the Company’s SPECTRUM® Variable Nicotine Research Cigarettes,
calling 22nd Century’s proprietary cigarettes an “important tool in
clinical studies for investigating… the impact of reduced nicotine
cigarettes on nicotine addiction…” Published in Tobacco Regulatory
Science, the independent study was conducted by a prestigious team
of 18 senior CDC scientists. Click here for a link to the complete
article.
Based in Oak Ridge, Tennessee and Atlanta, Georgia, the
independent scientific researchers critically showed that there is
a remarkable overall similarity in the chemistry and physical
properties of SPECTRUM® cigarettes as compared to commercial
cigarettes – with the noted exception of nicotine content which
“range[s] from very low to within the range reported for commercial
products (0.28 – 25.0 mg/g).”
22nd Century’s Vice President for Plant Biotechnology, Dr. Paul
Rushton, reported: “The CDC researchers also showed that 22nd
Century’s Very Low Nicotine SPECTRUM® cigarettes have reduced
levels of the cancer causing compounds NNN and NNK. The NNN levels
of SPECTRUM® cigarettes are within the lower one-third of the
concentration range reported for commercial cigarette products.
The NNK levels in SPECTRUM® cigarettes were lower than the
lowest published levels of NNK for commercial cigarette
products.” (emphasis added)
22nd Century is the only company in the world capable of
producing combustible cigarettes containing naturally grown tobacco
with non-addictive levels of nicotine. The independent researchers
indicated that SPECTRUM® variable nicotine cigarettes will help
regulatory agencies make vital decisions on the impact of reduced
nicotine levels for product addictiveness and smoking cessation
success. The study scientists also pointed out that more research
using the Company’s proprietary SPECTRUM® cigarettes is expected
due to multiple funding opportunities by the National Institutes of
Health
(https://prevention.nih.gov/tobacco-regulatory-science-program) and
the FDA
(http://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/default.htm).
Furthermore, as announced in May 2016, 22nd Century has launched a
new initiative to make the Company’s proprietary variable nicotine
research cigarettes available to accredited scientists and
governments around the globe. These new research cigarettes will be
available in any configuration and in any style requested by
researchers.
“The CDC researchers’ independent analysis of our SPECTRUM®
research cigarettes – and the multiple funding opportunities
stemming from the NIH and the FDA for further studies – confirms
that 22nd Century’s proprietary Very Low Nicotine cigarettes are
poised to make a major difference in the smoking cessation and
tobacco harm reduction arenas,” explained Henry Sicignano, III,
President and Chief Executive Officer of 22nd Century Group. “The
rapidly growing body of research surrounding our SPECTRUM® research
cigarettes is prompting public health officials around the world to
consider policies that allow consumers a choice between 22nd
Century’s Very Low Nicotine cigarettes and conventional brands. Our
product represents an important and fundamental change in the
industry.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. Visit www.xxiicentury.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616005829/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024